Drug Profile
Research programme: CD8+ regulatory T cell therapy - TxCell
Alternative Names: CAR engineered CD8+Treg cells - TxCell; CAR Tregs - TxCellLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Center for Research in Transplantation and Immunology
- Developer Center for Research in Transplantation and Immunology; Inserm Transfert; Nantes University Hospital; TxCell
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Multiple sclerosis; Transplant rejection
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in France
- 28 Jun 2021 No recent reports of development identified for preclinical development in Transplant-rejection in France
- 28 Jan 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in France